News Release
Result of GM
26 May 2023: Solgenics Limited ("Solgenics" or the "Company") (AIM: SGN) announces that, at the General Meeting ("GM") of the Company held today, the special resolutions to approve the cancellation of shares from AIM and to amend the Articles of Association were duly passed on a poll. The Company received authorised votes from 317,857,465 shares, representing 56% of the Company's shares in issue. Votes in support of both resolutions were 98% and 97% respectively.
The last day of dealings in the Company's Ordinary Shares on AIM will be Tuesday 6 June 2023 and the Cancellation will become effective at 7.00 a.m. on Wednesday 7 June 2023, subject to a dealing notice, as defined in the AIM Rules for Companies, being issued.
Enquiries
For further information please visit www.solgenics.com or contact:
| Solgenics: | Hanno Pengilly | +27 (0) 71 362 3566 |
| Liberum Capital Limited:
| Scott Mathieson, Edward Thomas, Kane Collings | +44 (0) 20 3100 2000 |
| Novum Securities Limited Joint Broker | Colin Rowbury | +44 (0) 20 7399 9427 |
|
Pimlico Advisory Ltd Investor Relations | Elizabeth Johnson | +44 (0) 777 56 55 927 |
About Solgenics
Solgenics is an African renewable energy development company focused on the development of a 300MW solar PV plus BESS power project in the Tete Province in northern Mozambique (the "Tete Solar Project").
It is the intention that the Tete Solar Project will connect to the Mozambique grid with target power offtakers in Mozambique and the Southern African Power Pool ("SAPP").
The Tete Solar Project takes full advantage of Mozambique's leading sustainable energy resources and is fully aligned with Government's objective to become a champion for energy transition impacting all Southern Africa.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.